首页> 外国专利> CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TERMINAL FRAGMENT BOUND TO ITS RECEPTOR

CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TERMINAL FRAGMENT BOUND TO ITS RECEPTOR

机译:人尿激酶纤溶酶原激活物氨基酸末端片段的晶体结构

摘要

Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR1-277) complexed with the amino terminal fragment (ATF) of uPA (uPA1-143) at a resolution of 1.9ú by X-ray crystallography. Three consecutive domains of uPAR (Dl, D2 and D3) form the shape of a thick-walled teacup with a cone shape cavity in the middle, which has a wide opening (25ú) and large depth (14ú). uPA1-143 inserts into the cavity of uPAR and forms a large interface. The structure provides the basis for high affinity binding between uPA and uPAR and suggests the Dl and D2 domain of uPAR and the GFD domain of uPA (uPA7-43) are primarily responsible for uPA-uPAR binding. This structure presents the first high resolution view of uPA-uPAR interaction, and provides, among other things, a new platform for designing uPA-uPAR inhibitors/antagonists.
机译:尿激酶型纤溶酶原激活剂(uPA)以高亲和力结合其细胞受体(uPAR),从而将纤溶酶从纤溶酶原的产生局限在多种细胞表面。本文公开了通过X射线晶体学以1.9μ的分辨率与uPA(uPA1-143)的氨基末端片段(ATF)复合的suPAR(uPAR1-277)的结构。 uPAR的三个连续域(D1,D2和D3)形成一个厚壁茶杯的形状,中间有一个圆锥形的空腔,开口宽(25ú),深度大(14ú)。 uPA1-143插入uPAR的腔中并形成一个较大的接口。该结构为uPA和uPAR之间的高亲和力结合提供了基础,并暗示了uPAR的D1和D2结构域以及uPA的GFD域(uPA7-43)主要负责uPA-uPAR结合。该结构展示了uPA-uPAR相互作用的第一个高分辨率视图,并且除其他外,提供了一个设计uPA-uPAR抑制剂/拮抗剂的新平台。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号